You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

persistent high-risk neuroblastoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma, Ganglioneuroblastoma Trial in Moscow (monoclonal antibodies GD2)

Recruiting
  • Neuroblastoma
  • Ganglioneuroblastoma
  • monoclonal antibodies GD2
  • Moscow, Russian Federation
    Research Institute of Pediatric Hematology, Oncology and Immunol
Oct 4, 2023

Neuroblastoma Trial (Naxitamab)

Not yet recruiting
  • Neuroblastoma
  • (no location specified)
Sep 18, 2023

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma Trial in United States (OPT-821 (QS-21), oral ß-glucan)

Recruiting
  • Neuroblastoma
  • +2 more
  • OPT-821 (QS-21)
  • oral β-glucan
  • Basking Ridge, New Jersey
  • +6 more
Sep 21, 2023

High-risk Neuroblastoma Trial in China (Dinutuximab Beta, 13 cis retinoic acid)

Active, not recruiting
  • High-risk Neuroblastoma
  • Dinutuximab Beta
  • 13 cis retinoic acid
  • Beijing, Beijing, China
  • +3 more
Dec 7, 2022

Neuroblastoma Trial in Minneapolis (Thiotepa, Cyclophosphamide, Melphalan)

Recruiting
  • Neuroblastoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

High-risk Neuroblastoma Trial in Charlotte (Naxitamab, Ceritinib)

Not yet recruiting
  • High-risk Neuroblastoma
  • Charlotte, North Carolina
    Levine Children's Hospital
Aug 4, 2022

Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)

Terminated
  • Neuroblastoma
  • antibody ch14.18
  • +4 more
  • Cologne, Germany
    University of Cologne
Nov 3, 2022

Neuroblastoma, CNS Tumor, Sarcoma Trial in Columbus (Cabozantinib)

Recruiting
  • Neuroblastoma
  • +2 more
  • Columbus, Ohio
    Nationwide Children's Hospital
Dec 20, 2022

Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma Trial (GPC2 CAR T cells)

Not yet recruiting
  • Refractory Neuroblastoma
  • +2 more
  • GPC2 CAR T cells
  • (no location specified)
Dec 21, 2022

Neuroblastoma Recurrent Trial in Worldwide (Naxitamab and GM-CSF in combination with irinotecan and temozolomide)

Terminated
  • Neuroblastoma Recurrent
  • Naxitamab and GM-CSF in combination with irinotecan and temozolomide
  • Hong Kong, Hong Kong
  • +2 more
Nov 8, 2022

Neuroblastoma Trial in New York (dietary supplement, drug, biological)

Recruiting
  • Neuroblastoma
  • β-glucan
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 5, 2022

Neuroblastoma, Pediatric Cancer Trial in New York (Cyclophosphamide, Topotecan, Vincristine)

Recruiting
  • Neuroblastoma
  • Pediatric Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 11, 2023

Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 1, 2022

HPV-Related Cervical Carcinoma, Low-Grade Squamous Intraepithelial Lesions, HPV Infection Trial in Wenzhou (CO2)

Recruiting
  • HPV-Related Cervical Carcinoma
  • +3 more
  • CO2
  • Wenzhou, Zhejiang, China
    first affiliated hospital of Wenzhou medical university
Sep 23, 2023

Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma Trial in United States (67Cu-SARTATE, 64Cu-SARTATE)

Recruiting
  • Neuroblastoma
  • +2 more
  • Phoenix, Arizona
  • +8 more
Jun 29, 2022

Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)

Recruiting
  • Neuroblastoma
  • +5 more
  • GD2-CART01
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

Recurrent Neuroblastoma Trial in Germany (metronomic therapy)

Recruiting
  • Recurrent Neuroblastoma
  • metronomic therapy
  • Bonn, Germany
  • +7 more
Nov 3, 2022

Neuroblastoma Trial in Houston (Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN

Active, not recruiting
  • Neuroblastoma
  • Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells
  • Cytoxan
  • Houston, Texas
    Texas Children's Hospital
Mar 25, 2022

Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8 With GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 2, 2022

Neuroblastoma, High-Risk Trial in New York (cyclophosphamide, NK cells, hu3F8)

Active, not recruiting
  • Neuroblastoma
  • High-Risk
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 14, 2022

Neuroblastoma Trial in Houston (SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP, SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2

Active, not recruiting
  • Neuroblastoma
  • SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
  • SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
  • Houston, Texas
    Texas Children's Hospital
Mar 3, 2022

Neuroblastoma Trial in New York (External beam radiotherapy, proton beam RT)

Recruiting
  • Neuroblastoma
  • External beam radiotherapy
  • proton beam RT
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 29, 2021

Acute Kidney Injury (Nontraumatic) Trial (Implementation of the KDIGO bundle))

Not yet recruiting
  • Acute Kidney Injury (Nontraumatic)
  • Implementation of the KDIGO bundle)
  • Münster, Germany
    University Hospital Münster; 1Department of Anesthesiology, Inte
Nov 4, 2022

Neuroblastoma (NB) Trial in New York (Irinotecan, temozolomide, Hu3F8)

Active, not recruiting
  • Neuroblastoma (NB)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 19, 2021